Centessa Pharmaceuticals (NASDAQ:CNTA) Lowered to Hold Rating by Truist Financial

Truist Financial downgraded shares of Centessa Pharmaceuticals (NASDAQ:CNTA) from a buy rating to a hold rating in a research report sent to investors on Monday, Marketbeat reports. The firm currently has $38.00 price target on the stock.

A number of other equities analysts also recently issued reports on the company. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Wednesday, January 14th. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $40.00.

Centessa Pharmaceuticals Stock Up 0.2%

Centessa Pharmaceuticals stock opened at $39.57 on Monday. The business has a fifty day moving average of $28.93 and a two-hundred day moving average of $26.31. The company has a quick ratio of 8.57, a current ratio of 8.57 and a debt-to-equity ratio of 0.21. The firm has a market cap of $6.12 billion, a P/E ratio of -26.92 and a beta of 1.25. Centessa Pharmaceuticals has a twelve month low of $10.95 and a twelve month high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.10). On average, analysts forecast that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 73,196 shares of the company’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the sale, the insider directly owned 65,925 shares in the company, valued at approximately $1,735,805.25. The trade was a 52.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 349,073 shares of company stock valued at $9,429,412. 7.09% of the stock is owned by insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. boosted its holdings in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after purchasing an additional 1,516 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after purchasing an additional 1,008 shares during the last quarter. Finally, Knott David M Jr purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.